Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738)
Leblond V, Chevret S, Dilhuydy MS, et al.
Key Points:
Preliminary clinical efficacy data of high-dose dexamethasone in combination with bortezomib in naive and pretreated elderly patients with WM reported
Combination well-tolerated and produced higher and durable response rates
Activity also noted in patients who did not respond to prior treatment with single-agent bortezomib
Implications:
- Bortezomib can be combined with high-dose dexamethasone as upfront or salvage therapy in elderly patients with WM
View the original abstract on the ASH website.
